| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
All patients fasted overnight before surgery. To exclude the potential influence of diurnal variations of salivation, the subject cases were performed uniformly at the time around midday. Subjects did not take any oral medication before surgery. Salivary function was evaluated before anesthesia using a modified standard table for judging the severity of xerostomia and pharyngoxerosis.11 This table consisted of two categories, including subjective and objective symptoms. Items for subjective symptoms were (1) a parched feeling of the mouth, (2) stickiness in the mouth, (3) strong yearning to drink (thirst), (4) pain in the oral cavity, (5) taste abnormality, (6) speech impairment, (7) difficult mastication, and (8) difficult swallowing. Objective symptoms were determined using the following nine items; (1) dryness of mucosa in the oral cavity, (2) redness of mucosa in the oral cavity, (3) ulcer of the oral cavity, (4) coating of the tongue surface, (5) smoothing of the tongue surface, (6) wrinkles and creases on the tongue surface, (7) cracks on the tongue surface, (8) redness of mucosa in the oropharynx, and (9) dryness of mucosa in the oropharynx. Each item was scored semiquantitatively from score 0 (no complaints) to score 3 (severe discomfort or findings). Total scores (from 0 to 51) were calculated using the standard table. Scores more than 25 were considered to indicate the presence of salivary dysfunction, and patients with scores >25 were excluded to avoid bias. Patients were randomized to the sevoflurane or propofol/remifentanil groups by using a random permuted block method.
Anesthesia In the propofol/remifentanil group, anesthesia was induced and maintained with propofol (Fresofol 2% Inj. Fresenius Kabi, Germany) and remifentanil hydrochloride (UltivaTM, Pharmacia and Upjohn NV/SA, Belgium) via a target-controlled infusion pump (Orchestra® pump, Fresenius Kabi Korea, Korea); patients lungs were ventilated using an air/oxygen mix (1:1). Rocuronium (1 mg/kg) was injected IV to facilitate endotracheal intubation. The target effect-site concentrations for propofol was 4–6 µg/mL and for remifentanil 3–5 ng/mL during induction; 3–5 µg/mL and 2–4 ng/mL for maintenance, respectively. Propofol and remifentanil target effect-site concentrations were titrated to maintain a mean arterial blood pressure of 80–100 mm Hg. In both groups 2% lidocaine 40 mg was given IV to reduce propofols injection pain before injection or infusion. Patients had standard ASA monitoring applied, including electrocardiography, noninvasive arterial blood pressure, pulse oximetry, and end-tidal CO2. Arterial blood pressures were recorded every 3 min. The settings for infusion target-controlled infusion pumps and vaporizers were identical in all subjects, although only one of the anesthetic techniques was actually used as determined by the earlier randomization. The IV lines from the pump to the patient were also hidden from the surgeon so that he was blind to which drug the patient received. The surgeon (H.S.J.) was blinded to the randomization, and at all times patients were also unaware of the anesthetic technique used.
Measurements Total oral and pharyngeal secretions after induction were determined by collecting them with frequent suction until the start of awakening from anesthesia. Salivary flow rates during anesthesia were defined as total amounts collected divided by total time (mL/min). Collected saliva was immediately sent to our central laboratory for determinations of osmolality, and total protein, amylase, and chloride concentrations. Salivary total protein and chloride secretion rates were calculated by multiplying the salivary flow rate by saliva total protein and chloride concentrations, respectively. In addition, the surgeon recorded the number of suctioning episodes required to clear the surgical field of secretions before beginning the actual operative procedure and any contribution of blood loss to the suctioned secretions. The two groups were then compared in terms of numbers of suctions. To determine the amounts of residual accumulated secretions in the oral cavity and pharynx at the end of surgery, secretions were collected separately and volumes and associated times were recorded (through d = 2.0 mm Laryngeal suction tip 8291.22, Richard Wolf GmbH, Germany). Data in the tables and figures are presented as mean values and standard deviations. The two groups were compared using a nonparametric comparison method (nonparametric Mann–Whitney test) because data were not normally distributed. Statistical significance was accepted for two-tailed P values of <0.05. RESULTS In the sevoflurane group, the end-tidal concentration of sevoflurane for anesthesia maintenance was mean 2.8% ± 0.92%. In the propofol/remifentanil group, the actual doses of propofol and remifentanil for maintenance were 3.4 ± 0.55 µg/mL and 3.2 ± 0.41 ng/mL, respectively. The salivary flow rates were determined by dividing total amounts of secretions collected by the durations of anesthesia (in minutes). When compared with preanesthetic baseline levels (<0.05 mL/min), salivary flow rates increased substantially in both study arms after induction. This increase was significantly more profound in the propofol/remifentanil group (0.53 ± 0.39 mL/min) than in the sevoflurane group (0.28 ± 0.15 mL/min) (P < 0.001). Collected secretions were submitted for composition analysis, and these showed high concentrations (>500,000 U/L) of amylase, which suggested that collected secretions were due mainly to salivary excretion (Table 2). The mean total protein concentration was slightly higher in the sevoflurane group, whereas the protein secretion rate was significantly higher in the propofol/remifentanil group, because salivary excretions were much greater in the propofol/remifentanil group. The mean chloride concentration was also higher in this group, although osmolality was similar in the two groups.
To evaluate the impact of salivary excretions on surgery, we counted the number of suction episodes required to clear the surgical field before starting the surgical procedures. In the sevoflurane group, the mean number of suction episodes before the procedures was 2.1 ± 1.5, whereas in the propofol/remifentanil group this was 5.0 ± 2.3 (P < 0.001). Thus, significantly more frequent suction episodes were needed in the propofol/remifentanil group. Mean residual volume of accumulated secretions after the main procedures was significantly higher in the propofol/remifentanil group (2.13 ± 0.56 mL) than in the sevoflurane group (0.45 ± 0.32 mL) (P < 0.001). To remove secretions from the oral cavity and oropharynx, more time was needed in the propofol/remifentanil group because secretions were more profuse and tenacious (propofol/remifentanil 69.8 ± 15.6 s vs sevoflurane 18.3 ± 12.4 s, P < 0.001) (Fig. 1).
DISCUSSION We evaluated the impact of anesthetics on salivary excretion with respect to securing an optimal surgical field during laryngeal surgery. We found salivary excretion is more rapid during propofol/remifentanil anesthesia than after a pure volatile anesthetic with sevoflurane. Several reports have compared sevoflurane inhaled anesthesia with propofol IV anesthesia during cystoscopy,12 minor gynecologic surgery,13 elective surgery,14 and in an outpatient setting.15,16 Primary outcome measures in these studies were anesthetic induction time, postoperative incidence of nausea and vomiting, recovery profiles, costs, and patient satisfaction.17 However, studies on the effects of sevoflurane and propofol/remifentanil on salivary excretion are limited and contradictory. One study concluded that propofol compared with methohexitol anesthesia does not affect mucus secretion or clearance from tracheal mucosa of healthy dogs,10 and another study found that propofol plus ketamine reduced salivary flow versus midazolam plus ketamine.9 In yet another study, a direct comparison between propofol and inhaled anesthesia (isoflurane) showed marked short-term hyposalivation in both groups.8 However, propofol anesthesia was also reported to induce increased salivation.6,7 In the propofol/remifentanil group, anesthesia was induced and maintained with propofol and remifentanil. From our data, both groups in this study showed similar arterial blood pressure values (slightly higher in the propofol/remifentanil group) during anesthesia, although direct measurement of catecholamine levels was not performed. Therefore, the direct effect of remifentanil via vagal or parasympathetic stimulation on salivation was thought to be minimal in the propofol/remifentanil group. In the sevoflurane group, we also used propofol for induction. Although we cannot precisely determine or evaluate the effect of propofol on the sevoflurane group from this study, the effect of propofol during induction was thought to be only temporary, considering the short onset and recovery time. Therefore, we think that the effect on salivation of propofol in the sevoflurane group was negligible. In laryngeal surgery, using a microscope, reducing the amount of secretions is critical for obtaining a satisfactory view, as is the case for oral and dental surgery. Our results showed a definite increase of salivary flow in the propofol/remifentanil group, which unfavorably affects the fine microscopic manipulations during laryngeal surgery. The effects of anesthetics on salivation may last throughout anesthesia. In particular, before the main procedure, more than five suction episodes were needed in the propofol/remifentanil group. We were unable to measure the number of suction episodes during surgery because the bleeding during surgery hindered counting the exact suction episodes for only salivary secretion. Composition analysis results also supported that the salivary excretion was greater in the propofol/remifentanil group. The mean total protein concentration was slightly higher in the sevoflurane group, whereas the protein secretion rate was significantly higher in the propofol/remifentanil group because salivary excretions were much greater in this group. Chloride in saliva also reflects salivary gland production.18 Therefore, the higher concentration and secretion rate of chloride in the saliva of the propofol/remifentanil group implies that salivary gland production was more stimulated in that group. This study has a limitation, which should be considered. It is possible that objective functions of the salivary gland might have been different in the two study groups. However, the risk of such a discrepancy between the two groups is minimal. The preanesthetic baseline level of secretion rates in some patients (n = 10) was uniformly <0.05 mL/min; therefore, the anesthetics were thought to mainly induce salivary excretion after induction. Presurgical patients likely experienced some sort of anxiety and their preanesthetic baseline salivary flow rates should not therefore be generalized as actual resting salivary flow rates in a larger or general population. In this study, the baseline salivary flow was used only as controls for comparison. We conclude that salivary excretion is greater under propofol/remifentanil anesthesia than under sevoflurane anesthesia, and that this may unfavorably affect the surgical field during laryngeal surgery.
Footnotes Accepted for publication February 15, 2008. The first two authors contributed equally to the paper. REFERENCES
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|